

## Report Card on provincial formulary reimbursement listings for biologic response modifiers

Arthritis Consumer Experts ranks publicly funded medication formularies based on whether or not they have listed five medically necessary arthritis medications for four of the most common types of inflammatory arthritis.

Formularies are awarded one point for each listing, and no points for declined listings, or for files remaining “under review”.

People with arthritis, and the doctors who treat them, deserve to be able to choose the medication most appropriate for the specific treatment plan they are developing. If after reading the report card you are disappointed with your province’s performance, please consider contacting your provincial government to make them aware of your concerns.

Four new biologics, which in future we will be adding to this Report Card, are on the way. They are not yet listed on any provincial formulary, so their addition to the Report Card does not change the ranking of any of the provinces. Anakinra (Kineret®) is listed on provincial formularies, but reimbursement varies. Provinces are not yet listing certolizumab pegol (Cimzia®), but resubmissions to the Common Drug Review are ongoing. Golimumab (Simponi®) has received a positive recommendation from the Common Drug Review, but is still awaiting formulary listing decisions from the provinces. Tocilizumab (Actemra®) is still under review by the Common Drug Review, so provinces are waiting for its recommendations before making any listing decisions.

### Biologic Chart : Updated July 2010

Generic Name (Brand Name)	abatacept (Orencia®)	adalimumab (Humira®)	etanercept (Enbrel®)	infliximab (Remicade®)	rituximab (Rituxan®)
<b>1st : Québec</b>					
rheumatoid arthritis	Listed — CBC	Listed — CBC	Listed — CBC	Listed — CBC	Listed — CBC
ankylosing spondylitis	Not Applicable	Listed — CBC	Listed — CBC	Listed — CBC	Not Applicable
juvenile idiopathic arthritis	Listed — CBC	Not Applicable	Listed — CBC	Listed — CBC	Not Applicable
psoriatic arthritis	In Clinical Trials	Listed — CBC	Listed — CBC	Listed — CBC	Not Applicable
<b>2nd : Saskatchewan</b>					
rheumatoid arthritis	Listed — CBC	Listed — CBC	Listed — CBC	Listed — CBC	Listed — CBC
ankylosing spondylitis	Not Applicable	Listed — CBC	Listed — CBC	Listed — CBC	Not Applicable
juvenile idiopathic arthritis	Listed — CBC	Not Applicable	Listed — CBC	Not Applicable	Not Applicable
psoriatic arthritis	In Clinical Trials	Listed — CBC	Listed — CBC	Listed — CBC	Not Applicable

*continued...*

## Biologic Chart : Updated July 2010

**Generic Name (Brand Name)**    **abatacept (Orencia®)**                      **adalimumab (Humira®)**                      **etanercept (Enbrel®)**                      **infliximab (Remicade®)**                      **rituximab (Rituxan®)**

### 2nd : Alberta

rheumatoid arthritis	Listed — ORC	Listed — CBC	Listed — CBC	Listed — CBC	Listed — CBC
ankylosing spondylitis	Not Applicable	Listed — CBC	Listed — CBC	Listed — CBC	Not Applicable
juvenile idiopathic arthritis	Listed — ORC	Not Applicable	Listed — CBC	Not Applicable	Not Applicable
psoriatic arthritis	In Clinical Trials	Listed — CBC	Listed — CBC	Listed — CBC	Not Applicable

### 4th : British Columbia

rheumatoid arthritis	Listed — CBC	Listed — CBC	Listed — CBC	Listed — CBC	Listed — CBC
ankylosing spondylitis	Not Applicable	Listed — CBC	Listed — CBC	Listed — CBC	Not Applicable
juvenile idiopathic arthritis	Under Review	Not Applicable	Listed — CBC	Not Applicable	Not Applicable
psoriatic arthritis	In Clinical Trials	Listed — CBC	Listed — CBC	Listed — CBC	Not Applicable

### 4th : New Brunswick

rheumatoid arthritis	Listed — CBC	Listed — CBC	Listed — CBC	Listed — CBC	Listed — CBC
ankylosing spondylitis	Not Applicable	Listed — CBC	Listed — CBC	Listed — CBC	Not Applicable
juvenile idiopathic arthritis	Listed — CBC	Not Applicable	Listed — CBC	Not Applicable	Not Applicable
psoriatic arthritis	In Clinical Trials	Listed — CBC	Listed — CBC	Declined Listing	Not Applicable

### 4th : Newfoundland and Labrador

rheumatoid arthritis	Listed — CBC	Listed — CBC	Listed — CBC	Listed — CBC	Listed — CBC
ankylosing spondylitis	Not Applicable	Listed — CBC	Listed — CBC	Listed — CBC	Not Applicable
juvenile idiopathic arthritis	Listed — CBC	Not Applicable	Listed — CBC	Not Applicable	Not Applicable
psoriatic arthritis	In Clinical Trials	Listed — CBC	Listed — CBC	Declined Listing	Not Applicable

### 7th : Nova Scotia

rheumatoid arthritis	Listed — CBC	Listed — CBC	Listed — CBC	Listed — CBC	Listed — CBC
ankylosing spondylitis	Not Applicable	Listed — CBC	Listed — CBC	Under Review	Not Applicable
juvenile idiopathic arthritis	Listed — CBC	Not Applicable	Listed — CBC	Not Applicable	Not Applicable
psoriatic arthritis	In Clinical Trials	Listed — CBC	Listed — CBC	Declined Listing	Not Applicable

continued ...

## Biologic Chart : Updated July 2010

**Generic Name (Brand Name)**    **abatacept (Orencia®)**                      **adalimumab (Humira®)**                      **etanercept (Enbrel®)**                      **infliximab (Remicade®)**                      **rituximab (Rituxan®)**

### 7th : Ontario

rheumatoid arthritis	Listed — CBC	Listed — CBC	Listed — CBC	Listed — CBC	Listed — CBC
ankylosing spondylitis	Not Applicable	Listed — CBC	Listed — CBC	Listed — CBC	Not Applicable
juvenile idiopathic arthritis	Under Review	Not Applicable	Listed — CBC	Not Applicable	Not Applicable
psoriatic arthritis	In Clinical Trials	Listed — CBC	Listed — CBC	Declined Listing	Not Applicable

### 9th : Prince Edward Island

rheumatoid arthritis	Listed — CBC	Listed — CBC	Listed — CBC	Listed — CBC	Under Review
ankylosing spondylitis	Not Applicable	Listed — CBC	Listed — CBC	Listed — CBC	Not Applicable
juvenile idiopathic arthritis	Under Review	Not Applicable	Unknown	Not Applicable	Not Applicable
psoriatic arthritis	In Clinical Trials	Listed — CBC	Listed — CBC	Under Review	Not Applicable

### 9th : NIHB\*

rheumatoid arthritis	Listed — CBC	Listed — CBC	Listed — CBC	Listed — CBC	Listed — CBC
ankylosing spondylitis	Not Applicable	Listed — CBC	Listed — CBC	Declined Listing	Not Applicable
juvenile idiopathic arthritis	Under Review	Not Applicable	Unknown	Not Applicable	Not Applicable
psoriatic arthritis	In Clinical Trials	Listed — CBC	Listed — CBC	Declined Listing	Not Applicable

### 11th : Manitoba

rheumatoid arthritis	Under Review	Listed — CBC	Listed — CBC	Listed — CBC	Listed — CBC
ankylosing spondylitis	Not Applicable	Listed — CBC	Listed — CBC	Unknown	Not Applicable
juvenile idiopathic arthritis	Under Review	Not Applicable	Unknown	Not Applicable	Not Applicable
psoriatic arthritis	In Clinical Trials	Listed — CBC	Listed — CBC	Unknown	Not Applicable

### 12th : Yukon

rheumatoid arthritis	Listed — CBC	Listed — CBC	Listed — CBC	Listed — CBC	Listed — CBC
ankylosing spondylitis	Not Applicable	Under Review	Under Review	Under Review	Not Applicable
juvenile idiopathic arthritis	Under Review	Not Applicable	Unknown	Not Applicable	Not Applicable
psoriatic arthritis	In Clinical Trials	Listed — CBC	Under Review	Under Review	Not Applicable

*continued...*

## About the report card:

Arthritis Consumer Experts graded each of the provinces by assigning a score based upon number of medications listed, number under review, and number of declined listings. In some cases, information was unavailable from a province or territory's website. This lack of transparency was reflected in grade assignments.

Because provincial formularies change frequently, we encourage you to contact the Ministry of Health in your province with questions you may have about medication listings of concern to you.

## Legend

**Declined Listing:** The formulary has decided not to reimburse patients being prescribed this medication.

**In Clinical Trials:** This medication is undergoing testing for use in treating this disease type.

**Listed - CBC:** Each province and territory has a process by which medications that are not normally included in the provincial, territorial or federal drug benefit lists are covered (or reimbursed). For the purposes of this report card, we have referred to these as case by case (or CBC) approvals.

**Listed - ORC:** Listed with Overly Restrictive Criteria. This medication has been listed with criteria not supported by medical evidence and considered unacceptable by Arthritis Consumer Experts.

**NOC:** Notice of Compliance from Health Canada has been issued for this medication for this form of arthritis.

**Not Applicable:** No Notice of Compliance (or NOC) has been issued for this medication for this form of arthritis.

**Under Review:** This drug has been approved by Health Canada and the province is currently deciding whether or not to reimburse for this drug.

**Unknown:** There is no public information available.

**CDR:** The Common Drug Review (CDR) is part of the Canadian Agency for Drugs and Technologies in Health. The Common Drug Review (CDR) conducts objective, rigorous reviews of the clinical and cost effectiveness of drugs, and provides formulary listing recommendations to the publicly funded drug plans in Canada (except Québec). (<http://cadth.ca/index.php//cdr>)

\* Note: People living in the Northwest Territories and Nunavut, who do not have private health insurance, have coverage for those drugs listed on the federal Non-Insured Health Benefits (NIHB) Formulary.



#200B 1228 Hamilton Street, Vancouver BC V6B 6L2  
t: 604.974.1366 tf: 1.866.974.1366 f: 604.974.1377

e: [feedback@jointhehealth.org](mailto:feedback@jointhehealth.org)  
[www.jointhehealth.org](http://www.jointhehealth.org)

### Disclaimer

The material contained in this newsletter is provided for general information only. It should not be relied on to suggest a course of treatment for a particular individual or as a substitute for consultation with qualified health professionals who are familiar with your individual medical needs. Should you have any healthcare related questions or concerns, you should contact your physician. You should never disregard medical advice or delay in seeking it because of something you have read in this or any newsletter.